Seeking Alpha

Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday,...

Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday, spurred on today by a downgrade to Perform at Oppenheimer, citing a lack of near-term catalysts for the drug maker over the near term.
Comments (1)
  • cholee65
    , contributor
    Comments (38) | Send Message
     
    Amgen has to be looking to beef up their pipeline now, they should look at ASTX. Here's a decent company that CEO's last company Genzyme bought for a billion: http://bit.ly/xrPxih
    23 Feb 2012, 01:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector